Benjamin F. Edwards & Company Inc. boosted its position in Pfizer, Inc. (NYSE:PFE) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,551 shares of the biopharmaceutical company’s stock after purchasing an additional 4,679 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Pfizer were worth $3,142,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Fisher Asset Management LLC lifted its position in Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after purchasing an additional 1,275,832 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after purchasing an additional 377,404 shares during the period. Macquarie Group Ltd. lifted its position in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after purchasing an additional 228,405 shares during the period. Boston Partners lifted its position in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after purchasing an additional 1,649,801 shares during the period. Finally, Bank of Montreal Can lifted its position in Pfizer by 1.2% in the second quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock valued at $622,562,000 after purchasing an additional 227,682 shares during the period. Hedge funds and other institutional investors own 68.99% of the company’s stock.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now directly owns 124,774 shares of the company’s stock, valued at $4,242,316. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock worth $15,813,961 over the last quarter. 0.06% of the stock is currently owned by company insiders.

A number of equities research analysts recently commented on PFE shares. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG restated a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research report on Monday, July 31st. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $38.10.

Pfizer, Inc. (NYSE PFE) opened at 36.34 on Friday. The company’s 50 day moving average price is $35.25 and its 200 day moving average price is $33.76. The firm has a market capitalization of $216.13 billion, a P/E ratio of 26.58 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.60.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the business posted $0.64 EPS. Pfizer’s revenue was down 1.9% compared to the same quarter last year. Analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. Pfizer’s payout ratio is presently 94.12%.

ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Position Raised by Benjamin F. Edwards & Company Inc.” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/15/pfizer-inc-pfe-position-raised-by-benjamin-f-edwards-company-inc.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.